Adjuvant therapy with gemcitabine and stereotactic body radiation therapy versus gemcitabine alone for resected stage II pancreatic cancer: a prospective, randomized, open-label, single center trial

BACKGROUND: The role of adjuvant radiation in pancreatic adenocarcinoma (PDAC) remains unclear. We aimed to investigate the efficacy of gemcitabine combined with stereotactic body radiation therapy (SBRT) as adjuvant therapy for resected stage II PDAC. METHODS: In this single-center randomized contr...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Tao, Bai, Xueli, Wei, Qichun, Shui, Yongjie, Lao, Mengyi, Chen, Wen, Huang, Bingfeng, Que, Risheng, Gao, Shunliang, Zhang, Yun, Chen, Wei, Wang, Ji, Liang, Tingbo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9361660/
https://www.ncbi.nlm.nih.gov/pubmed/35941566
http://dx.doi.org/10.1186/s12885-022-09974-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9361660/
https://www.ncbi.nlm.nih.gov/pubmed/35941566
http://dx.doi.org/10.1186/s12885-022-09974-7

Ejemplares similares